THE GENERAL HOSPITAL CORPORATION;THE BROAD INSTITUTE INC.;DANA-FARBER CANCER INSTITUTE, INC.
发明人:
FRITSCH, EDWARD F.,HACOHEN, NIR,ROONEY, MICHAEL STEVEN,SHUKLA, SACHET ASHOK,BACHIREDDY, PAVAN,WU, CATHERINE J.,SUN, JING
申请号：
CA2986235
公开号：
CA2986235A1
申请日:
2016.05.20
申请国别(地区):
CA
年份:
2016
代理人:
摘要：
Disclosed herein in one aspect is a pharmaceutical composition comprising a plurality of neoantigenic peptides and a pharmaceutically acceptable carrier, each neoantigenic peptide comprising a tumor-specific neoepitope capable of binding to an HLA protein in a subject, each tumor-specific neoepitope comprising a tumor-specific mutation present in a tumor, wherein (a) the composition comprises neoantigenic peptides comprising tumor-specific mutations present in at least 1% of subjects in a population of subjects suffering from cancer； (b) the composition comprises neoantigenic peptides comprising tumor-specific neoepitopes which bind to HLA proteins present in at least 5% of subjects in the population； and (c) the composition comprises at least one neoantigenic peptide capable of eliciting an immune response against a tumor present in at least 5% of the subjects in the population of subjects suffering from cancer.
